March 21, 2024
GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy emerged as the most heavily pitched product by sales reps for GPs through vis-a-vis detailing in January, according to a monthly Intage survey. Intage’s “Impact Track” detailing track survey asks some 4,000 GPs/hospital...read more